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Abstract A hallmark event in transmissible spongiform en-
cephalopathies is the conversion of the physiological prion
protein into the disease-associated isoform. A natural poly-
morphism at codon 129 of the human prion gene, resulting in
either methionine or valine, has profound influence on suscept-
ibility and phenotypic expression of the disease in humans. In this
study, we investigated the local propensity of synthetic peptides,
corresponding to the region of the polymorphism and containing
either methionine or valine, to adopt a L-sheet-rich structure
similar to the pathological protein. Circular dichroism studies
showed that the methionine-containing peptide has a greater
propensity to adopt a L-sheet conformation in a variety of
experimental conditions. The higher L-sheet tendency of this
peptide was also associated with an increased ability to aggregate
into amyloid-like fibrils. These results suggest that methionine at
position 129 of the prion protein increases its susceptibility to
switch to the abnormal conformation, in comparison with the
presence of valine at the same position. ß 2001 Federation of
European Biochemical Societies. Published by Elsevier Science
B.V. All rights reserved.
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1. Introduction
Transmissible spongiform encephalopathies (TSE), also
known as prion diseases, are a group of devastating degener-
ative disorders of the brain that a¡ect humans and animals.
The group includes Creutzfeldt^Jakob disease (CJD), kuru,
Gerstmann^Straussler syndrome (GSS) and fatal familial in-
somnia (FFI) in humans as well as scrapie and bovine spongi-
form encephalopathy in animals. TSE can have diverse ori-
gins, namely infectious, familial and sporadic [1]. Although
the aetiology and pathogenesis are not fully understood, the
disease is associated with an abnormally shaped form of a
natural protein named prion protein (PrPC). The formation
of the disease-associated isoform (PrPSc) appears to be the key
step in the pathogenesis and involves changes in the secondary
structure of the protein [1,2]. PrPSc is the only known compo-
nent of the infectious agent and has the capability to self-
replicate at the expense of PrPC [2]. No chemical di¡erences
have been detected to distinguish the two PrP isoforms, but
they can be experimentally di¡erentiated by four properties
[2,3] : (a) PrPSc is partially resistant to proteolytic degradation,
whereas PrPC is sensitive to proteolysis ; (b) PrPC is a soluble
protein, while PrPSc is stubbornly insoluble and becomes de-
posited in infected brain parenchyma; (c) PrPC is mainly com-
posed of K-helical conformation, while PrPSc is rich in L-sheet
secondary structure; (d) PrPSc is able to replicate itself in vitro
and in vivo by converting PrPC into PrPSc [4,5].
The human prion protein is a product of a single host gene
located on the short arm of chromosome 20 that contains two
exons. The sequence of the translated product is 253 amino
acids long, contains ¢ve amino-terminal octapeptide repeats,
two glycosylated sites and one disulphide bridge [1,3]. In ad-
dition, there are two signal sequences in the amino- and car-
boxy-terminal parts, which are removed during processing
and a glycosylphosphatidylinositol anchor attaches the pro-
tein to the outer surface of the cell membrane [6]. The
three-dimensional structure of several fragments as well as
the full-length recombinant PrP have been obtained from dif-
ferent species [7^11]. The nuclear magnetic resonance (NMR)
structure of the mature recombinant human prion protein, as
well as the protein from several other species, predicts a struc-
tured globular domain extending from residues 125 to 228 and
an N-terminal £exible and disordered region. The globular
domain contains three K-helices comprising the residues
144^154, 173^194, and 200^228 and an anti-parallel L-sheet
consisting of two short strands comprising the residues 128^
131 and 161^164 [9]. Based on immunological, biochemical,
and molecular modeling studies, it has been proposed that the
fragment 90^145 of PrP is the main region of the protein that
switches to the L-sheet conformation upon the formation of
PrPSc [12^20].
Model peptides have been used extensively to study the
contributions of di¡erent fragments of PrP to its properties
and to elucidate the mechanism of PrP conversion [20]. Pep-
tides spanning the PrP sequence 109^141 can reproduce in
vitro some of the characteristics of the transition between
PrPC and PrPSc [21], including a random to L-sheet conforma-
tional change, which result in acquisition of protease resis-
tance and aggregation into rod-shaped ¢brils [21]. In addition,
the interaction of this fragment with PrPC induces the normal
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protein to acquire some properties of the pathological iso-
form, including protease resistance and insolubility [22].
Moreover, several peptides around the PrP sequence 100^
150 inhibit the interaction between the two PrP isoforms re-
sulting in prevention of the in vitro conversion of PrPC into
PrPSc in a cell-free system [15,18]. Finally, the fragment 106^
126 of the human protein causes nerve cell death by apoptosis
and induces hypertrophy and proliferation of astrocytes and
activation of microglial cells in vitro [17,23]. These data sug-
gest that the central PrP fragment (around residues 106^140)
might be the nidus at which conformational change is initiated
during the conversion of PrPC into PrPSc.
Several mutations in the prion gene have been associated
with inherited forms of TSE [1^3]. In humans there is a poly-
morphism at codon 129, where an ATG or GTG results in
either a methionine (Met) or a valine (Val) at that position. A
large body of evidence indicates that this polymorphism alone
or in conjunction with mutations in the prion gene modulates
disease susceptibility and phenotypic expression of human
TSE [24^30]. However, the molecular mechanism by which
the polymorphism a¡ects disease pathogenesis is unknown.
The aim of this study was to evaluate the in£uence of poly-
morphism at position 129 on the properties of the protein and
its propensity to undergo conformational changes, using mod-
el peptides containing the human PrP109^136 sequence and
bearing either Met or Val at position 129.
2. Materials and methods
2.1. Peptide synthesis
PrP fragments spanning the sequence 109^136 of human PrP and
bearing Met (PrP109^136M, sequence MKHMAGAAAA-
GAVVGGLGGYMLGSAMSR) or Val (PrP109^136M, sequence
MKHMAGAAAAGAVVGGLGGYVLGSAMSR) at position 129
were synthesised in solid phase at Neosystem Inc. Peptides were pu-
ri¢ed by HPLC and purity (s 95%) was evaluated by peptide se-
quencing and laser desorption mass spectrometry. Stock solutions of
the peptides were prepared in water/0.1% tri£uoroacetic acid and
stored lyophilised in aliquots at 370‡C. Concentration of the stock
solution was estimated by amino acid analysis.
2.2. Circular dichroism (CD)
Spectra of solutions containing PrP synthetic peptides (50 WM),
prepared in the bu¡ers described in Figs. 1^3, were recorded in a
Jasco J-810 spectropolarimeter at 25‡C using a 0.1 cm path-length
cell. Spectra of ¢ve scans were accumulated at 1 nm intervals over
the wavelength range 190^260 nm and bu¡er spectrum obtained under
identical conditions was subtracted. Results are expressed as molar
ellipticity in units of deg cm2 dmol31, and data were analysed by the
Jasco Secondary Structure Estimation software (version 1.00, 1998)
that uses the Yang algorithm [31] to obtain the percentages of di¡er-
ent secondary structure motifs.
2.3. Studies of amyloid formation in vitro
Aliquots of PrP synthetic peptides at di¡erent concentrations in
0.1 M Tris, pH 7.4, were incubated for various times at 37‡C. Amy-
loid formation was quantitatively assessed by a £uorometric assay
based on the £uorescence emission of thio£avine T (ThT), as previ-
ously described [32]. Additional characterisation of the ¢brillogenesis
was performed by electron microscopy after negative staining [33].
Samples were placed on carbon formvar-coated 300 mesh nickel grids
and stained for 60 s with 2% uranyl acetate. Grids were analysed
using a Zeiss EM 10 electron microscope at 80 kV.
3. Results
3.1. In£uence of polymorphism on peptide conformation
Secondary structural studies of peptides containing the se-
quence 109^136 of human PrP and bearing either Met or Val
at position 129 were carried out under a variety of conditions,
using CD. Studies in aqueous solutions at neutral pH showed
signi¢cantly di¡erent CD spectra in the far UV depending
upon the amino acid at position 129 (Fig. 1). Analysis of
the spectra to obtain the estimated content of di¡erent sec-
ondary structural motifs (Tables 1 and 2) revealed that both
peptides consisted of a mixture of L-sheet, L-turn and unor-
dered structures, with no evident K-helical conformation.
However, the relative content of L-sheet and random coil
was signi¢cantly di¡erent, because PrP109^136M has a higher
Fig. 1. CD spectra of PrP109^136 peptides bearing Met or Val at
position 129. 50 Wg of each peptide was dissolved in 350 Wl of 10
mM Tris, pH 7.4 and immediately the CD spectrum was recorded
as described in Section 2. The spectrum of bu¡er was subtracted
and CD data converted to mean residue ellipticity. Solid line,
PrP109^136M; dotted line, PrP109^136V.
Fig. 2. E¡ect of TFE on the CD spectra of PrP fragments. 50 Wg of
PrP109^136M (A) or PrP109^136V (B) was dissolved in 350 Wl of
10 mM Tris, pH 7.5 containing either 20% (solid line), 40% (dotted
line) or 60% (dashed line) of TFE. Spectra were recorded as de-
scribed in Section 2 and the bu¡er subtracted to obtain the ¢nal
spectra that were converted to mean residue ellipticity using the Jas-
co software.
FEBS 25535 10-12-01 Cyaan Magenta Geel Zwart
C. Petchanikow et al./FEBS Letters 509 (2001) 451^456452
L-sheet and a lower random coil level that the homologous
Val-containing peptide. Short peptides usually adopt a mainly
unordered structure in aqueous solution and it is a common
practice to add some organic solvents (in particular tri£uoro-
ethanol (TFE)) to try to mimic the environment on the in-
terior of a protein molecule and thus evaluate the putative
structure of the fragment in the context of the entire protein
[34]. In the presence of 20% TFE both peptides become more
structured (Fig. 2), which is re£ected in the decrease in the
random coil content (Tables 1 and 2). However, while
PrP109^136M increased its L-sheet content by 17% to reach
43.8% of this structural motif (Table 1), the content of L-sheet
in the PrP109^136V remained unchanged at around 11% (Ta-
ble 2). The increase in structure of the latter peptide is in the
form of K-helix, reaching 12% of this motif at 20% TFE
(Table 2). At higher concentrations of TFE both peptides
behave similarly (Fig. 2, Tables 1 and 2), which is not surpris-
ing because high quantities of TFE will induce secondary
structure in any peptide, regardless of the sequence.
Structural studies at di¡erent pH in aqueous solvents
showed that whereas the CD spectrum of PrP109^136M
does not change between pH 3.0 and 10.7 (Fig. 3A), the spec-
trum of the Val-containing fragment varied signi¢cantly in the
same pH range (Fig. 3B). At acid pH, there is virtually no L-
sheet structure in PrP109^136V, while the content of this mo-
tif increased to 28.6% at pH 10.7, reaching a similar pattern as
the Met-containing peptide (Tables 1 and 2). These data sug-
gest that a low pH, similar to the conditions in which the
conversion may occur intracellularly in vivo, determines a
large di¡erence in the propensity of each peptide to adopt a
conformation closer to the normal or to the pathological PrP
isoform.
3.2. In£uence of polymorphism on peptide aggregation
As reported earlier, PrP fragments containing the sequence
109^141 and 106^126 form amyloid ¢brils in vitro, a phenom-
enon that has also been observed in the brain of a great
proportion of TSE cases [35]. In order to evaluate the e¡ect
of the polymorphism at codon 129 on the ability of the pep-
tides to make amyloid, ¢brillogenesis studies were carried out
in vitro. Both PrP109^136M and PrP109^136V were able to
form amyloid ¢brils after incubation at 37‡C in 0.1 M Tris,
pH 7.4, as evaluated by the £uorescence emission of the amy-
loid binding dye ThT (Fig. 4) and by electron microscopy
(Fig. 5). The amount of ¢brils formed was dependent upon
the concentration of the peptide (Fig. 4A) and the time of
incubation (Fig. 4B). Under both experimental conditions,
the amount of amyloid obtained with the Met-containing pep-
tide was dramatically higher than for the Val-containing ana-
logue. For example, after 3 days of incubation at a concen-
tration of 3 mg/ml, PrP109^136M formed ¢ve-fold more
amyloid than PrP109^136V (Fig. 4B). This conclusion was
qualitatively supported by the electron microscopic analysis
of the aggregates (Fig. 5). Morphologically, the ¢brils con-
sisted of unbranched ¢laments with a diameter of 5^10 nm
and more than 200 nm in length, similar to amyloid ¢brils
extracted from the brain of people a¡ected by Alzheimer’s
Table 1
Secondary structure of PrP109^136M in various conditions
Condition K-Helix (%) L-Sheet (%) L-Turn (%) Random (%)
Bu¡er 0 26.7 21.4 51.9
20% TFE 0 43.8 7.8 48.3
40% TFE 19.2 43.1 0 37.7
60% TFE 37.2 21.9 0 41.0
pH 3.0 0 22.8 25.3 51.9
pH 5.0 0 18.0 29.8 52.3
pH 6.0 0 20.6 27.0 52.5
pH 7.0 0 24.9 23.4 51.7
pH 8.0 0.5 27.7 23.5 48.3
pH 9.0 2.3 25.2 24.9 47.6
pH 10.7 1.4 28.6 22.2 47.8
Fig. 3. E¡ect of pH on the CD spectra of PrP fragments. 50 Wg of
PrP109^136M (A) or PrP109^136V (B) was dissolved in 350 Wl of
various bu¡ers adjusted to di¡erent pHs. The bu¡ers used were the
following: 10 mM sodium citrate at pH 3.0; 10 mM sodium acetate
at pH 5.0; 10 mM MES at pH 6.0; 10 mM sodium phosphate at
pH 7.0; 10 mM Tris at pH 8.0 and pH 9.0; and 10 mM carbo-
nate^bicarbonate bu¡er at pH 11.0. Spectra were recorded as de-
scribed in Section 2 and the contribution of each bu¡er was sub-
tracted.
Table 2
Secondary structure of PrP109^136V in various conditions
Condition K-Helix (%) L-Sheet (%) L-Turn (%) Random (%)
Bu¡er 0 10.7 27.2 62.2
20% TFE 12.0 11.0 30.4 46.7
40% TFE 17.5 42.6 0 39.9
60% TFE 36.0 22.5 0 41.5
pH 3.0 0 2.7 36.7 60.6
pH 5.0 0 0 37.8 62.4
pH 6.0 0 0 37.2 62.8
pH 7.0 0 10.9 30.2 58.8
pH 8.0 0 18.2 28.6 53.3
pH 9.0 2.2 23.5 26.1 48.2
pH 10.7 2.0 25.6 24.8 47.6
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disease or GSS [35] and those produced in vitro by incubating
the human recombinant PrP90^231 [36]. No evident morpho-
logical di¡erences were observed between ¢brils formed by the
two peptides.
4. Discussion
A central event in the pathogenesis of TSE is the conversion
of a natural protein isoform (PrPC) into the L-sheet-rich, ag-
gregated, toxic and protease resistance conformer (PrPSc).
Several epidemiological studies have demonstrated that a nat-
ural polymorphism at position 129 (Met/Val) of PrP is the
most important risk factor known for human TSE
[24,26,28,29,37,38]. Both Met and Val homozygotes are
over-represented, while heterozygous cases are under-repre-
sented in CJD [39]. About 40% of the normal population is
Met-homozygous, however respectively 78%, 60% and 100%
of patients a¡ected by the sporadic, iatrogenic and variant
forms of CJD are Met-homozygous [24]. These data suggest
that the presence of Met at position 129 confers a higher
susceptibility for the protein to be converted into the patho-
genic isoform. The polymorphism has also been shown to
alter the neuropathological pattern of lesions in sporadic
CJD, the glycoform pro¢le of protease-resistant PrPSc and
the duration and severity of the disease [25^27,40]. A study
involving 300 patients showed that Met-homozygotes develop
a more aggressive phenotype characterised by a short dura-
tion of disease (4.5 months), while heterozygotes and Val-ho-
mozygotes have a much longer disease duration (14.3 and 16.9
months, respectively) [27]. Val-homozygosity seems to cause
damage preferentially in the deep grey matter, while Met-ho-
mozygosity seems to target mainly cortical structures [26].
Codon 129 polymorphism also in£uences the phenotypic ex-
pression of mutations elsewhere in the prion gene [38,41^43].
For example, people with a mutation at codon 178 resulting
in a change of aspartic acid to asparagine develop either fam-
ilial CJD or FFI depending on whether the amino acid at
codon 129 is Val or Met, respectively [30].
Despite the clear importance of PrP polymorphism at posi-
tion 129 in the disease propensity and pathogenesis, the mo-
lecular mechanism of this e¡ect is unknown. Experimental
and computational modeling studies of the three-dimensional
structure of PrP have been unable to identify any signi¢cant
di¡erence between the two isoforms. In addition, no di¡erence
was reported on the in vitro thermodynamic stability of re-
combinant PrP bearing either Met or Val at position 129 [44].
Structural studies have shown evidence for hydrogen bonding
between Asp178 and Tyr128, which might provide a structural
basis for the in£uence of the polymorphism on the disease
phenotype that segregates with the mutation Asp178Asn
[45]. In addition, it has been reported that a slightly di¡erent
conformation of recombinant Met- or Val-containing PrP iso-
forms was induced upon copper binding [46].
In this study we show that a synthetic peptide containing
the human PrP109^136 sequence and bearing Met at position
129 has a higher propensity to adopt a L-sheet structure as
observed by CD, than the homologous Val-containing pep-
tide. The higher L-sheet propensity of the former resulted in
an increase in aggregation into amyloid-like ¢brils. Some of
the major biochemical di¡erences between PrPC and PrPSc are
Fig. 4. Amyloid ¢brillogenesis of PrP109^136M and PrP109^136V.
Aliquots of each peptide were incubated at di¡erent concentrations
(A) during 5 days at 37‡C or a ¢xed concentration of 3 mg/ml dur-
ing di¡erent times (B). Amyloid formation was measured by the
ThT £uorometric assay as described in Section 2 and is expressed
as arbitrary £uorescence units. In both graphs, squares represent the
PrP109^136M samples and circles the PrP109^136V samples.
Fig. 5. Electron microscope photographs of amyloid ¢brils formed by PrP fragments. 60 Wg of PrP109^136M (a) or PrP109^136V (b) was incu-
bated for 5 days in 20 Wl of 0.1 M Tris, pH 7.4. Samples were loaded in electron microscope grids and stained with uranyl acetate as described
in Section 2. Grids were visualised with 80U magni¢cation.
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precisely the greater levels of L-sheet secondary structure re-
sulting in aggregation of the pathological conformer [1,2].
Therefore, our ¢ndings suggest that Met at position 129 pro-
vides a greater local propensity for the conversion of PrPC to
PrPSc than Val at that position. This conclusion, which is
counter-intuitive, because Val is usually considered a stronger
L-sheet-forming amino acid than Met [47,48], has to be eval-
uated in the context of the entire protein. It is possible that
the di¡erences in L-sheet propensity are mainly in the local
structure and might not be seen easily in a larger fragment or
in the entire protein. Using a similar approach, it was re-
ported previously that synthetic peptides spanning the region
106^136 of human PrP and containing Met or Val at position
129 did not show a signi¢cant di¡erence in secondary struc-
ture as analysed by CD studies [49]. One possible explanation
for the di¡erences between these results and ours is that the
extension of the peptide toward the N-terminus in the study
by Smith and co-workers (106 versus 109) precludes the for-
mation of L-sheets in the model peptide [49]. This explanation
is supported by studies from Nguyen and co-workers [50] who
demonstrated that a peptide spanning the sequence 109^122
of Syrian hamster PrP adopts a L-sheet structure, whereas the
104^122 peptide has a random coil structure in aqueous solu-
tion. The reason for the dramatically di¡erent conformations
adopted by these two peptides is unknown, but it is likely to
be related to a distinct balance between hydrophobic and
hydrophilic amino acids [50]. Indeed, PrP104^122 has one
more positively charged residue than PrP109^122, which
could minimise intermolecular interactions that are required
for L-sheet formation. The same charge di¡erence is also ob-
served between PrP109^136 (used in this study) and PrP106^
136 (used in the study by Smith et al. [49]).
According to the NMR solution structure of human PrPC,
residue 129 lies on a short L-strand comprising residues 128^
131, which forms an antiparallel L-sheet with a second L-
strand spanning residues 161^164 [9]. It has been proposed
that this short L-sheet might be a nucleation site around
which the loop connecting the L-sheet as well as the ¢rst K-
helix are transformed into several longer L-strands during
PrPCCPrPSc conformational transition [7]. Based on the re-
sults described here, we propose that Met at position 129 in-
duces a higher local propensity to extend the short L-sheet
present in the normal protein into a larger sheet, which results
in an increase in the rate of PrP conversion to the pathological
isoform. This mechanism might explain the association of
Met129 polymorphism with an increased risk of developing
sporadic and variant CJD.
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